Wantstats
Company ProfilePremium

Galderma Laboratories

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
Galderma Laboratories - Healthcare showcase

Industry

Healthcare

Services

Consumer SolutionsDermal FillersSkin SenescenceMedical SolutionsAcne
G

Galderma Laboratories Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Galderma Laboratories Overview

Established in 1981 and headquarters in Lausanne, Switzerland. Galderma is one of the big names of the pharmaceutical industry in dermatology, over the past three decades galderma key area of focus is to provide innovative solutions in the field of dermatology, which consists of acne, rosacea, psoriasis and other steroid-responsive dermatoses, onychomycosis, pigmentary disorders, skin cancer and other various fields in skin care.

Currently Galderma is a global leader in dermatology and has strategic partnerships with brands like Soolantra, Tri-Luma, Loceryl, BenzacEpiduo, Oracea, Differin, Mirvaso, Cetaphil, Excipial, Daylong, Restylane, Emervel and many other brands.

Presently galderma is operating in over 80+ countries, providing patients with skin care needs and has an employee work force of over 6000 employees. The company has worldwide network of distributers and 34 wholly-owned affiliates.

Strategy

Galderma focuses on partnerships with different health-care practitioners across the world to meet the skin health needs of people. The company is also involved in the research and development of scientifically defined and medically-proven solutions for the skin to improve its product line. Moreover, with the recent acquisition of Galderma by a renowned consortium, the new management team focuses on a pureplay dermatology business, with outstanding prospects built on its existing quality portfolio, team and innovation.

Company Snapshot

$87,286.83M

Revenue

SWOT Analysis

Strengths

  • Worldwide distribution network
  • Highly skilled workforce
  • Robust R&D for the development of innovative products
  • Innovative product range
  • Trusted brand name
  • Global presence
  • Strong R&D base
  • Robust R&D capabilities
  • Considerable investment for research in aesthetic field
  • Presence in the global market
  • Strong R&D
  • Innovative products
  • Product approvals
  • Strong brand portfolio with broad range of medical and consumer health solutions. Well positioned for long-term growth in highly attractive dermatology sector with its refocus on food & nutrition since July 2019
  • Strong geographic presence with one of the best geographically diversified revenue sources. The company operates from 50 sites in 40 countries with 5 manufacturing sites and aims to increase the presence in the US and China, launch new products, and focus on international expansion
  • Expansion of the business by opening new business facility. Such as company opened new toxin manufacturing facility designed to meet the production and safety requirements of QM1114 liquid formulation of botulinum toxin type A
  • Positive pipeline growth with the clinical study ‘DREAM (Dysport Real-world Evaluation and Measured satisfaction’ with a 95% of patient’s high levels of satisfaction. Top-line results showed that 95% of patients treated with Dysport (abobotulinumtoxinA), and 97% of patients thought the result of the treatment looked natural
  • Proven track records in building sustainable high-growth businesses in pharmaceutical and consumer industries
  • Strong R&D activities
  • Well-established distribution network and global presence
  • Robust sales and marketing capabilities
  • Partnerships with major public and private organizations

Weaknesses

  • Past legal issues
  • Limited penetration in developing markets
  • Ceasing the operations of numerous factories in various regions such as Egerkingen
  • Limited presence in developing markets
  • Portfolio limited to the dermatology segment
  • Limited presence in emerging economies
  • Company is exposed to the recession and price risk mainly from investment in mutual funds and investment in equity
  • Limited success outside core businesses and one of the leading organizations in its industry but it has faced challenges in moving to other product segments
  • Need more investment for new technologies looking at the scale of expansion and different geographies the company is planning to expand into. Company needs to put more money in technology
  • Operational failures

Opportunities

  • Increasing the product portfolio
  • Mergers & acquisitions
  • Launch of new products
  • Strategic mergers & acquisitions
  • Enhancing the products portfolio by launching products
  • Collaborations with regional players to expand geographic boundaries
  • Collaboration with authorities, physicians and dermatologists to advance skin treatment. In 2016, Ipsen acquired the intellectual property for Galderma’s liquid toxin in some of the APAC region. The companies significantly strengthened their collaboration by prolonging their partnership until 2036 and increasing the scope of R&D
  • New environmental policies will create opportunities by creating a level playing field for the company in the industry. It represents a great opportunity for the company to drive home its advantages in new technology and gain market share in the new product category
  • Expansion of products offering
  • Acquisitions could strengthen growth rates and profitability

Threats

  • Negative consequences of healthcare reforms in major markets
  • Intense competition
  • Changing customer preference
  • Stringent government regulations
  • Intense competition in the botulinum toxin market by the presence of other major players in the market such as Allergan, Medytox, and Merz, among others to introduce new therapeutic applications of botulinum toxin
  • Fluctuating exchange rates, company is exposed to foreign currency risk arising out of transactions in foreign currency
  • Rising raw material price can pose a threat to the profitability of the company and changing consumer buying behavior which could be a threat to the existing physical infrastructure driven supply chain model

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
May 2018ApprovalGalderma received the Food and Drug Administration (FDA) approval for its Restylane Lyft a hyaluronic acid (HA) dermal filler for the back of the hands of patients over the age of 21
October 2017ApprovalGalderma received the FDA approval for Restylane Silk hyaluronic acid dermal filler. Restylane Silk is specially designed for lip augmentation and is injected via a cannula.
December 2016ApprovalGalderma received the FDA approval for the Restylane Refyne and Restylane Defyne dermal fillers used for laugh lines.
–PartnershipGalderma, along with The European Society for Dermatological Research (ESDR), LEO Pharma, and Celgene partnered to form The Skin Science Foundation (SSF). The SSF will pioneer next-generation skincare by using cutting-edge techniques to better understand skin health.
–ExpansionThe company opened a new office in Kuala Lumpur, Malaysia, which will help the company to accelerate growth in this country.
–ExpansionThe parent company, Nestlé, launched two factories in the China Medical City in Taizhou, Jiangsu Province. With this expansion, the company increased its foothold in the Chinese market for facial fat transfer.
–ApprovalGalderma received the FDA approval for Restylane Silk hyaluronic acid dermal filler. Restylane Silk is specially designed for lip augmentation and is injected via a cannula. Thus, the company expanded its portfolio of products in the facial fat transfer market.
–ExpansionThe company invested 46 million Canadian dollars (USD 35.46 million) to extend the capacity of its Canadian factory located in Baie D’Urfé, Québec. Through this, the company strengthened its position in the Canadian market.
–ExpansionThe company invested 54 million Swiss Franc (USD 55.15 million) in a new skin health products factory in the Brazilian state of São Paulo, to meet the rising demand for facial aesthetic products in the country and across Latin America. Thereby bracing its position in the Latin American market.
May 2018Product ApprovalThe FDA approved Restylane Lyft for treatment of wrinkles and folds. It was the first injectable filler (hyaluronic acid filler) used for wrinkles and folds which was approved by the FDA.
October 2019Manufacturing LicenseGalderma SA received a manufacturing license to set up a new state-of-the-art manufacturing facility in Uppsala, Sweden. With this facility, the company will be able to cater to the needs of European customers.
January 2016AgreementIpsen Pharma (France) and Galderma SA went into an agreement for the distribution of Dysport in the Asia-Pacific region. Galderma received product development, promotion and distribution rights of Dysport for the Asia-Pacific region.
December 2019ApprovalGalderma received and approval from the European Union (EU) for its AKLIEF for patients from 12 years of age and older.
October 2019ApprovalGalderma received the FDA approval for AKLIEF-containing retinoid molecule. It is the first retinoid molecule to receive approval for the treatment of acne in over 20 years.
January 2019ExpansionGalderma announced the opening of a new office in Malaysia. With this, the company aims to accelerate growth in this region.

Product Offering

  • Galderma Laboratories
    • Consumer Solutions
    • Dermal Fillers
    • Skin Senescence
    • Medical Solutions
    • Acne
    • Melasma
    • Seborrheic dermatitis
    • Skin senescence
    • Cosmetics

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales rose from USD 87,286.8 Mn in 2016 to USD 93,400.4 Mn in 2018.
Galderma Laboratories — By Business Segment
Series (USD Mn)201620172018
Sales87,286.887,490.293,400.4
R&D Expenditure1,693.71,698.21,723.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →